SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-13-434859
Filing Date
2013-11-08
Accepted
2013-11-08 14:02:18
Documents
11
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d592963d10q.htm 10-Q 623697
2 EX-31.1 d592963dex311.htm EX-31.1 9430
3 EX-31.2 d592963dex312.htm EX-31.2 9451
4 EX-32.1 d592963dex321.htm EX-32.1 4391
5 EX-32.2 d592963dex322.htm EX-32.2 4577
  Complete submission text file 0001193125-13-434859.txt   3720900

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT aegr-20130930.xml EX-101.INS 504810
7 XBRL TAXONOMY EXTENSION SCHEMA aegr-20130930.xsd EX-101.SCH 33334
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aegr-20130930_cal.xml EX-101.CAL 60424
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aegr-20130930_def.xml EX-101.DEF 75288
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE aegr-20130930_lab.xml EX-101.LAB 263954
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aegr-20130930_pre.xml EX-101.PRE 180647
Mailing Address 101 MAIN STREET SUITE 1850 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1850 CAMBRIDGE MA 02142 (617) 500-7867
Aegerion Pharmaceuticals, Inc. (Filer) CIK: 0001338042 (see all company filings)

IRS No.: 202960116 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34921 | Film No.: 131203913
SIC: 2834 Pharmaceutical Preparations